Board summary
Key figures
32,779
Registered population
58.6% aged 18–64
19.0%
Aged 65+
ICB 14.9% · England 17.9%
33.9%
Ethnic minority (non-White)
25.5% Asian · England 9.6%
39.9%
In IMD quintile 1
ICB 40.7% · England 21.0%
~12,890
Core20 residents (est.)
Resident basis; registered basis ~12,687 · see page 3
4,848
Hypertension register
+2.90% in 3 yrs · England +5.60%
359
SMI register
9.9% of Bolton (LAD)'s
739
COPD register
Reviews -1.93% in 3 yrs
Forecast to 2030
5,085
Hypertension patients, 2030
+237 on today
57.3%
QRISK ≥20% on statins, 2030
-2.46pp over 3 yrs
4.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review coverage fell over three years.
Annual asthma reviews remain 70.9% (England 65.7%), but fell 7.5% over 2023 to 2025 (England +4.4%), leaving 636 patients unreviewed, which may reflect recall.
Respiratory, blood pressure and smoking achievement lead England.
Achievement exceeds England for COPD reviews at 82.4% (76.4%), under-80 hypertension control at 70.5% (67.8%), and smoking cessation support offered at 97.6% (94.2%).
Population, age and ethnicity
A list of 32,779 patients combines 19.0% aged 65+ with 25.5% Asian residents
Chorley Roads Network PCN has 32,779 registered patients. Those aged 65+ make up 19.0% (6,232 patients), above Bolton (14.7%), NHS Greater Manchester Integrated Care Board (14.9%) and England (17.9%). Patients aged 0-17 comprise 22.4% (7,327), below Bolton (23.7%) but above the ICB (21.8%) and England (19.6%). Census estimates show Asian / Asian British usual residents represent 25.5% (Bolton 20.1%, ICB 13.6%, England 9.6%), ranging to 37.5% at Wyresdale Road Surgery and 25.9% at Dalefield Surgery, alongside 0.7% Gypsy or Irish Traveller residents (Bolton 0.2%, ICB 0.1%, England 0.1%).
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Bolton (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Bolton LA) | 1,923 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Bolton LA) | 958 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Bolton LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 39.9% of patients and varies sharply across practices
Core20 patients comprise 39.9% of registered lists across Chorley Roads Network PCN, above England (21.0%) but below Bolton (47.8%) and NHS Greater Manchester ICB (40.7%). Modelled weighted practice share is 38.7%. Wyresdale Road Surgery has the highest concentration at 78.4% (3,066 estimated Core20 patients), Dalefield Surgery holds the largest volume with 5,439 estimated Core20 patients (70.3%), and Heaton Medical Centre records 14.5% (1,528 estimated patients). Targeted primary care initiatives could balance concentrated neighbourhood outreach with high-volume clinical management.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
359
SMI register
1.06% recorded prevalence
152
Learning disability register
0.45% recorded prevalence
16
Care homes, 286 beds
In the PCN catchment
9.8%
Provide unpaid care
Bolton (LAD), Census 2021
The PCN records 359 patients on its severe mental illness register (1.1%) and 152 on its learning disability register (0.5%, trailing Bolton, ICB and England rates of 0.6%). Catchment data shows 16 care homes with 286 beds, which do not confirm GP registration. Lower recorded learning disability prevalence may reflect differences in case-finding or coding, which local clinical audits could verify.
Severe mental illness: physical health checks
SMI blood pressure checks reached 84.0% (England 83.4%), with Dalefield Surgery at 73.9%. Annual BMI recording was 81.4% (England 82.1%), rising +2.7 pp over 2023 to 2025 (England +5.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,848
Hypertension register
+2.90%
Register growth, 3 yrs
Bolton (LAD) +4.70% · England +5.60%
−3.19pp
BP control, under 80
≤140/90 · −0.83pp aged 80+
+237
More patients by 2030
Forecast 5,085 (15.23%)
Hypertension case-finding and control
Recorded hypertension prevalence is 14.4% (4,848 patients), matching NHS Greater Manchester ICB (14.4%) but below Bolton (14.8%) and England (15.2%), ranging from 9.8% at Wyresdale Road Surgery to 18.3% at Spring House Surgery. Over 2023 to 2025, the register grew +2.9% (England +5.6%). Blood pressure control under age 80 is 70.5% (England 67.8%), but fell 4.3% over 2023 to 2025 (England +3.2%). Recent blood pressure recording is 87.1% (England 90.0%), falling 3.0% over three years (England +3.6%). Observation periods were not supplied. Declining recording and control could reflect recall gaps that local clinical audit would verify.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy coverage is 62.0% (Bolton 63.0%, England 63.6%, ICB 67.0%), falling 3.8% over 2023 to 2025 (England +6.2%). In 2026, prescribing of lipid-regulating drugs for patients aged 65+ was 8,771 items per 1,000 (Bolton 10,001, ICB 11,661, England 18,056).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 54,661 | £1.80 | £1.94 | £1.86 | £98,390 |
| Cardiovascular (all), 2025 | 73,654 | £4.16 | £3.15 | £3.33 | £306,401 |
In 2026, the PCN prescribed 54,661 items of lipid-regulating drugs at £1.80 per item (Bolton £1.81, England £1.86, ICB £1.94), totalling £98,390 in annual spend. Across these items, spend was £3,280 less than at England's unit cost and £7,653 less than at NHS Greater Manchester Integrated Care Board's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−7.50%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−5.52%
Asthma prevalence, PCN 3-yr % change
Asthma review coverage is 70.9% (England 65.7%) and COPD review coverage is 82.4% (England 76.4%), but asthma reviews fell 7.5% over 2023 to 2025 (England +4.4%). This leaves an estimated scale gap of about 640 patients without a recorded review across the 2,187-patient register. Prescribing of asthma management items for ages 5-19 is 1,977 per 1,000 (England 1,488), which local audit could review alongside routine recalls.
Cancer register and children's immunisation
Cancer prevalence is 3.5% across 1,172 registered patients (England 3.8%). In Q1 2025/26 childhood immunisations, 24-month coverage is below the 95.0% standard for 6-in-1 (88.3%, England 92.2%) and MMR dose 1 (87.0%, England 88.3%). In contrast, separate age-5 cohorts reached 97.0% for MMR dose 1 and 94.1% for MMR dose 2, which local audit could review for timing of catch-up.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of staged cancers across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (England 55.3%), sitting 19.4 pp below the 75.0% national ambition by 2028 and requiring about 2,270 extra early-stage diagnoses across 11,679 staged cases. Known-stage cancers were 70.8% of all 16,492 registered ICB cases. These system figures do not measure PCN performance. Locally, recorded cancer prevalence is 3.5% (1,172 patients). Cervical screening coverage (women aged 25-49) fell 3.2% over 2023 to 2025 (England -1.0%) to 64.2% (England 66.8%), dropping to 55.9% at Dalefield Surgery and 55.7% at Wyresdale Road Surgery. Lower uptake may reflect recall barriers to evaluate locally across participating practices.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Bolton NHS Foundation Trust achieved 69.7% on the 62-day cancer referral to treatment standard, 15.3 pp below the 85.0% standard, trailing England (71.2%), NHS Greater Manchester Integrated Care Board (75.7%), Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust (76.8%) and Northern Care Alliance NHS Foundation Trust (78.6%). Bolton met the 28-day faster diagnosis standard at 80.5% (standard 75.0%; England 79.3%) and the 31-day combined standard at 96.5% (standard 96.0%; England 92.5%). Diagnostic 6+ week waits were 25.3% for cystoscopy and 19.4% for computed tomography. These secondary care delays could affect treatment timelines for referred patients.
| Pathways within standard (%) | Bolton | Wrightington, Wigan and Leigh | Northern Care Alliance | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.48 | 82.80 | 75.20 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.50 | 89.04 | 94.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 69.66 | 76.78 | 78.65 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Bolton | Wrightington, Wigan and Leigh | Northern Care Alliance | England |
|---|---|---|---|---|
| MRI | 2.05 | 0.49 | 5.09 | 21.40 |
| CT | 19.40 | 7.78 | 4.10 | 9.92 |
| Echocardiography | 3.48 | 24.37 | 31.48 | 28.48 |
| Colonoscopy | 1.33 | 6.10 | 40.04 | 30.83 |
| Gastroscopy | 2.06 | 12.54 | 36.48 | 29.02 |
| All 15 DM01 tests | 15.78 | 14.36 | 15.71 | 23.14 |
| Community services activity | Bolton residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 49,315 | 573,310 |
| Referrals | 4,075 | 94,470 |
| Patients with a contact | 17,765 | 183,535 |
Community services (residents of Bolton), Jun 2026 (provisional). In June 2026, provisional community services dataset figures show adults aged 65 and older accounted for 51.6% of all community contacts for Bolton borough residents, representing 25,460 of 49,315 contacts. These borough-level resident figures describe wider system activity rather than PCN-level delivery. High borough-level community service use among older adults is consistent with substantial demand for intermediate care across local neighbourhoods.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF overall achievement ranged from 90.6% at Wyresdale Road Surgery to 92.7% at Spring House Surgery (England 92.5%). In vaccination and immunisation, Cornerstone Surgery achieved 21.7%, Dalefield Surgery recorded 41.6% (a 41.6 pp range), and Wyresdale Road Surgery reached 63.3%. Cornerstone Surgery also had a 14.0% personalised care adjustment rate.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Cornerstone | 106 | 32.5 | 74.4% | 67.9% | 86.3% |
| Spring House | 98 | 20.4 | 63.7% | 68.6% | 81.5% |
| Heaton | 116 | 14.5 | 57.5% | 76.2% | 79.1% |
| Dalefield Surgery | 113 | 70.3 | 48.4% | 76.9% | 77.8% |
| Wyresdale Road | 109 | 78.4 | 71.0% | 64.7% | 74.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
23 of 25 tracked measures trail England over three years across clinical pathways
Over 2023 to 2025, 23 of 25 tracked measures trail England's three-year change. The widest relative declines include asthma reviews, falling 7.5% (England +4.4%), dementia register prevalence down 4.3% (England +6.0%), QRISK ≥ 20% lipid therapy falling 3.8% (England +6.2%), and diabetes HbA1c control without frailty falling 4.0% (England +4.4%). Conversely, smoking cessation support offered rose +0.5 pp (England +0.1 pp) to 97.6% (England 94.2%), and heart failure reviews rose +0.5% (England +8.7%). These diverging trajectories could reflect varied recall processes, which clinical audit would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
Dementia register
QRISK statin treatment
Diabetes HbA1c control
Heart failure reviews
Smoking support (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Bolton (LAD) | Asset | PCN | Bolton (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 16 (286 beds) | n/a | Schools (catchment) | 31 | n/a |
| Children's centres | 2 | 18 | Places of worship | 26 | 144 |
| Libraries | n/a | 7 | Primary schools (LA maintained) | 10 | 61 |
| Primary academies | 3 | 32 | Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and inhaler recall
Asthma review coverage is 70.9% of the 2,187 register (England 65.7%), falling 7.5% over 2023 to 2025 (England +4.4%), leaving a scale gap of 636 patients alongside 1,977 asthma items per 1,000 aged 5-19 (England 1,488). Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Cardiovascular and diabetes secondary prevention recall
Over 2023 to 2025, QRISK ≥ 20% lipid therapy fell 3.8% to 62.0% (England +6.2%, 63.6%), recent BP recording across the 4,848 hypertension register fell 3.0% to 87.1% (England +3.6%, 90.0%), and non-frail diabetes HbA1c ≤ 58 mmol/mol fell 4.0% to 53.5% (England +4.4%, 57.4%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Learning disability register coding validation
Recorded learning disability prevalence is 0.5% (152 patients across the 32,779 list), below England and Bolton (both 0.6%), giving an unadjusted benchmark gap range of +41 to +47 patients. For discussion: audit clinical records for uncoded learning disability diagnoses and check social-care records where sharing exists. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored access review (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach and capacity (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Targeted SMI physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Early childhood immunisation catch-up (p6) | 6-in-1 complete primary course at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review and inhaler recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Cardiovascular and diabetes secondary prevention recall (p12) | Hypertension register · Hypertension patients with a recent BP reading · Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Learning disability register coding validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
